SEC Form 4 · accession 0000899243-17-001652
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Braslyn Ltd.
10% Owner
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 18, 2017 | P | 16,200 | $5.50 | A | 2,710,042 | D | |
| Common StockF1 | Jan 19, 2017 | P | 21,085 | $5.48 | A | 2,731,127 | D | |
| Common StockF1 | Jan 20, 2017 | P | 23,873 | $5.42 | A | 2,755,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These securities are owned directly by Braslyn Ltd. ("Braslyn") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Joe Lewis, (vi) Rodney W. Lappe, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Neil Reisman, (x) Shehan B. Dissanayake and (xi) Christopher Fuglesang. Joe Lewis is the sole indirect beneficial owner of and controls Braslyn.